Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
Journal of Hematotherapy & Stem Cell Research|July 17, 2001
Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantationB Fehse, A Chukhlovin, K Kühlcke, et al.
Cancer Treatment Reports|February 1, 1982
High-dose AMSA and bone marrow rescue in patients with solid tumorsA R Zander, G Spitzer, S Legha, et al.
Annals of Hematology|March 22, 2002
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphomaM Hänel, N Kröger, S Sonnenberg, et al.
Bone Marrow Transplantation|June 13, 2000
Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantationB Simonsson, T Tötterman, P Hokland, et al.
Klinische Padiatrie|September 23, 1998
[Treatment of hemophagocytic lymphohistiocytosis, HLH, with bone marrow transplantation]M Dürken, E M Schneider, R Blütters-Sawatzki, et al.
Bone Marrow Transplantation|May 12, 2009
Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donorsO W Neth, U Bacher, P Das, et al.
Bone Marrow Transplantation|November 15, 2005
Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantationJ Dahlke, N Kröger, T Zabelina, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-upA R Zander, C Schmoor, N Kröger, et al.
Bone Marrow Transplantation|May 25, 1999
Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrowA R Zander, T Zabelina, N Kröger, et al.
Pageof 20